Formulary guidance and transparency from P&T to point of care

MMIT Reality Check on Ovarian Cancer (Nov 2018)

Posted by Matt Breese on Nov 23, 2018

Find me on:

According to our recent payer coverage analysis for ovarian cancer treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for ovarian cancer treatments shows that across all drugs in the class, only an average of 17% of Medicare lives are not covered for at least one of the drugs.

MMIT_Reality Check_OvarianCancer_4Q2018

Data snapshot as of Q4 2018

Trends: The FDA in June expanded the label of Avastin (bevacizumab) to include its use in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, for the treatment of stage III or stage IV epithelial ovarian, fallopian tube or primary peritoneal cancer following initial surgery resection. Via AIS Health.

To read the full Reality Check on Ovarian Cancer treatments with key findings on clinical characteristics, drug market access and payer coverage, please click on the button below: 


View Reality Check

Topics: Specialty, Market Access, Payer, Branding & Marketing